Vascularites
Veille bibliographique : Vascularites
Les articles sont classés du plus ancien au plus récent, n’hésitez pas à utiliser la barre de recherche pour filtrer les résultats par date par exemple.
| Guillevin L et al. French Vasculitis Study Group. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014 Nov 6;371(19):1771-80. | Lire le résumé |
| Miloslavsky EM et al. Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group. Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2014 Nov;66(11):3151-9 | Lire le résumé |
| Sacri AS et al. Clinical characteristics and outcomes of childhood-onset ANCA-associated vasculitis: a French nationwide study. Nephrol Dial Transplant. 2015 Feb 12. | Lire le résumé |
| Jachiet M et al. French Vasculitis Study Group. The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients. Arthritis Rheumatol. 2015 Feb;67(2):527-34. | Lire le résumé |
| Pagnoux C et al. French Vasculitis Study Group. Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheumatol. 2015 Apr;67(4):1117-27. | Lire le résumé |
| Miloslavsky EM et al. for the Rituximab in ANCA-Associated Vasculitis–Immune Tolerance Network Research Group. Outcomes of Nonsevere Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Treated With Glucocorticoids Arthritis Rheumatol. 2015 June;67(6):1629-36. | Lire le résumé |
| McGeoch L et al. ; Vasculitis Clinical Research Consortium. Cardiac Involvement in Granulomatosis with Polyangiitis. J Rheumatol. 2015 Jul;42(7):1209-12. | Lire le résumé |
| Puéchal X et al. Long-term outcomes of the WEGENT trial on remission-maintenance for granulomatosis with polyangiitis or microscopic polyangiitis. Arthritis Rheumatol Hoboken NJ. 16 oct 2015. | Lire le résumé |
| Rahmattulla C et al. Incidence of Malignancies in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Diagnosed Between 1991 and 2013. Arthritis Rheumatol. 2015 Dec;67(12):3270-8. | Lire le résumé |
| Mohammad AJ et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis. févr 2016; 75(2):396‑401. | Lire le résumé |
| Crickx E et al. Intravenous Immunoglobulin as an Immunomodulating Agent in Antineutrophil Cytoplasmic Antibody-Associated Vasculitides: A French Nationwide Study of Ninety-Two Patients. Arthritis Rheumatol Hoboken NJ. mars 2016;68(3):702‑12. | Lire le résumé |
| Cartin-Ceba R et al. Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes. Arthritis Rheumatol Hoboken NJ. juin 2016;68(6):1467‑76. | Lire le résumé |
| Unizony S et al. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis. juin 2016;75(6):1166‑9. | Lire le résumé |
| Jachiet M et al. Anti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Data on Seventeen Patients. Arthritis Rheumatol Hoboken NJ. sept 2016;68(9):2274‑82. | Lire le résumé |
| Miloslavsky EM et al. Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive and ANCA-Negative Patients With Granulomatosis With Polyangiitis (Wegener’s): Distinct Patient Subsets. Arthritis Rheumatol Hoboken NJ. déc 2016;68(12):2945‑52. | Lire le résumé |
| Morishita KA et al. Early Outcomes in Children with Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis (AAV). Arthritis Rheumatol Hoboken NJ. 2017 Mar 28 | Lire le résumé |
| Tan JA et al. Mortality in ANCA-associated vasculitis: a meta-analysis of observational studies. Ann Rheum Dis. 2017 May 3 | Lire le résumé |
| Wechsler ME et al. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med. 2017 18;376(20):1921–32. | Lire le résumé |
| Bossuyt X et al. Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol. 2017 Nov;13(11):683–92. | Lire le résumé |
| (1) Schreiber A et al. C5a receptor mediates neutrophil activation and ANCAinduced glomerulonephritis. J Am Soc Nephrol. 2009 Feb;20(2):289-98. (2) Xiao H et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol. 2014 Feb;25(2):225-31. (3) Jayne DRW et al. CLEAR Study Group. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. J Am Soc Nephrol. 2017 Sep;28(9):2756-2767. | Lire le résumé |
| Kronbichler A, Kerschbaum J, Gopaluni S, Tieu J, Alberici F, Jones RB, et al. Trimethoprim–sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis. Annals of the Rheumatic Diseases. 2018 Jun 27;annrheumdis-2017-212861 | Lire le résumé |
| Banerjee S, Bagheri M, Sandfort V, Ahlman MA, Malayeri AA, Bluemke DA, et al. Vascular calcification in patients with large-vessel vasculitis compared to patients with hyperlipidemia. Seminars in Arthritis and Rheumatism [Internet]. 2018 Sep [cited 2018 Nov 26]; Available from: https://linkinghub.elsevier.com/retrieve/pii/S0049017218304098 | Lire le résumé |
| Jones RB, Jones RB, Hiemstra TF, Ballarin J, Blockmans DE, Brogan P, Bruchfeld A, et al. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. Annals of the Rheumatic Diseases. 2019 Jan 5;annrheumdis-2018-214245 | Lire le résumé |
| Berti A, Matteson EL, Crowson CS, Specks U, Cornec D. Risk of Cardiovascular Disease and Venous Thromboembolism Among Patients With Incident ANCA-Associated Vasculitis: A 20-Year Population-Based Cohort Study. Mayo Clinic Proceedings. 2018 May;93(5):597–606 Mourguet M, Chauveau D, Faguer S, Ruidavets JB, Béjot Y, Ribes D, et al. Increased schemic stroke, acute coronary artery disease and mortality in patients with granulomatosis with polyangiitis and microscopic polyangiitis. Journal of Autoimmunity. 2019 Jan;96:134–41 Kang A, Antonelou M, Wong NL, Tanna A, Arulkumaran N, Tam FWK, et al. High Incidence of Arterial and Venous Thrombosis in Antineutrophil Cytoplasmic Antibody–associated Vasculitis. The Journal of Rheumatology. 2019 Mar;46(3):285–93 | Lire le résumé |
| Jones RB, Furuta S, Cohen Tervaert JW, Hauser T, Luqmani R, Morgan MD, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis. juin 2015;74(6):1178‐82 Stones JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. N Engl J Med. 15 juill 2010;363(3):221‐32 Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. The Lancet. mai 2014;383(9930):1731‐8 Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, et al. Infliximab Treatment of Intravenous Immunoglobulin–Resistant Kawasaki Disease. J Pediatr. déc 2008;153(6):833‐838.e6 | Lire le résumé |
| Gregersen JW, Erikstrup C, Ivarsen P, Glerup R, Krarup E, Keller KK, et al. PR3-ANCA-associated vasculitis is associated with a specific motif in the peptide-binding cleft of HLA-DP molecules. Rheumatology [Internet]. 1 avr 2019 [cité 26 avr 2019]; Disponible sur: https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/kez111/5425275 | Lire le résumé |
| De Graeff N, Groot N, Brogan P, Ozen S, Avcin T, Bader-Meunier B, et al. European consensus-based recommendations for the diagnosis and treatment of rare paediatric vasculitides – the SHARE initiative. Rheumatology. 1 avr 2019 ;58(4) :656 71 | Lire le résumé |
| Zhang H, Watanabe R, Berry GJ, Nadler SG, Goronzy JJ, Weyand CM. CD28 Signaling Controls Metabolic Fitness of Pathogenic T Cells in Medium and Large Vessel Vasculitis. J Am Coll Cardiol. avr 2019;73(14):1811 23 | Lire le résumé |
| Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 3 juill 2019;annrheumdis-2019-215672 | Lire le résumé |
| Walsh M, Merkel PA, Peh C-A, Szpirt WM, Puéchal X, Fujimoto S, et al. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. N Engl J Med. 2020 Feb 13;382(7):622–31 | Lire le résumé |
| Charles P, Perrodeau É, Samson M, Bonnotte B, Néel A, Agard C, et al. Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Randomized Trial. Ann Intern Med [Internet]. 2 juin 2020 [cité 23 juin 2020]; | Lire le résumé |
| McClure ME, Zhu Y, Smith RM, Gopaluni S, Tieu J, Pope T, et al. Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models. Rheumatology [Internet]. 3 nov 2020 [cité 23 nov 2020] | Lire le résumé |
| Jayne DRW, Merkel PA, Schall TJ, Bekker P. Avacopan for the Treatment of ANCA-Associated Vasculitis. N Engl J Med. 18 févr 2021;384(7):599‑609. | Lire le résumé |
| Furuta S, Nakagomi D, Kobayashi Y, Hiraguri M, Sugiyama T, Amano K, et al. Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial. JAMA. 1 juin 2021;325(21):2178. | Lire le résumé |
| Giorgiutti S, Dieudonne Y, Hinschberger O, Nespola B, Campagne J, Rakotoarivelo HN, et al. Prevalence of antineutrophil cytoplasmic antibody (ANCA)‐associated vasculitis and spatial association with quarries in a French Northeast region. Arthritis Rheumatol. 21 avr 2021;art.41767. | Lire le résumé |
| Brink M, Berglin E, Mohammad AJ, Lundquist A, Gjertsson I, Alexeyenko A, et al. Protein profiling in pre‐symptomatic individuals separates MPO‐ANCA and PR3‐ANCA vasculitides. Arthritis Rheumatol. 19 déc 2022;art.42425. | Lire le résumé |
| Berti A, Hillion S, Konig MF, Casal Moura M, Hummel AM, Carmona E, et al. Autoreactive plasmablasts after B cell depletion with rituximab and relapses in ANCA ‐associated vasculitis. Arthritis Rheumatol. 25 oct 2022;art.42388. | Lire le résumé |
| Sánchez Álamo B, Moi L, Bajema I, Faurshou M, Flossmann O, Hauser T, et al. Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis. Nephrol Dial Transplant. 6 janv 2023;gfac320. | Lire le résumé |
| Hellmich B, Sanchez-Alamo B, Schirmer JH, Berti A, Blockmans D, Cid MC, Holle JU, Hollinger N, Karadag O, Kronbichler A, Little MA, Luqmani RA, Mahr A, Merkel PA, Mohammad AJ, Monti S, Mukhtyar CB, Musial J, Price-Kuehne F, Segelmark M, Teng YKO, Terrier B, Tomasson G, Vaglio A, Vassilopoulos D, Verhoeven P, Jayne D. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2023 Mar 16:ard-2022-223764. doi: 10.1136/ard-2022-223764. Epub ahead of print. PMID: 36927642.Références | Lire le résumé |
| Sorin B, Iudici M, Guerry MJ, Samson M, Bielefeld P, Maillet T, Nouvier M, Karras A, Meyer L, Lavigne C, Régent A, Durel CA, Fabre M, Charles P, Raimbourg Q, Lanteri A, Pugnet G, Rivière F, Pineton de Chambrun M, Cacoub P, Le Guenno G, Jourdain P, Mekinian A, Paule R, Dion J, Legendre P, Cohen P, Guillevin L, Puéchal X, Terrier B; French Vasculitis Study Group. Induction failure in granulomatosis with polyangiitis: a nationwide case-control study of risk factors and outcomes. Rheumatology (Oxford). 2023 Feb 27:kead098. doi: 10.1093/rheumatology/kead098. Epub ahead of print. PMID: 36847447 | Lire le résumé |
| Smith RM, Jones RB, Specks U, Bond S, Nodale M, Al-Jayyousi R, Andrews J, Bruchfeld A, Camilleri B, Carette S, Cheung CK, Derebail V, Doulton T, Ferraro A, Forbess L, Fujimoto S, Furuta S, Gewurz-Singer O, Harper L, Ito-Ihara T, Khalidi N, Klocke R, Koening C, Komagata Y, Langford C, Lanyon P, Luqmani R, McAlear C, Moreland LW, Mynard K, Nachman P, Pagnoux C, Peh CA, Pusey C, Ranganathan D, Rhee RL, Spiera R, Sreih AG, Tesar V, Walters G, Wroe C, Jayne D, Merkel PA; RITAZAREM co-investigators. Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial. Ann Rheum Dis. 2023 Mar 23:ard-2022-223559. doi: 10.1136/ard-2022-223559. Epub ahead of print. PMID: 36958796. | Lire le résumé |
| Benichou N, Charles P, Terrier B, Jones RB, Hiemstra T, Mouthon L, Bajema I, Berden A, Thervet E, Guillevin L, Jayne D, Karras A; French asculitis Study Group (FVSG) and European Vasculitis Society (EUVAS) investigators. Proteinuria and hematuria after remission induction are associated with outcome in ANCA-associated vasculitis. Kidney Int. 2023 Jun;103(6):1144-1155. doi: 10.1016/j.kint.2023.02.029. Epub 2023 Mar 20. PMID: 36940799. | Lire le résumé |
| Satrapova V, Sparding N, Genovese F, Karsdal MA, Bartonova L, Frausova D, Honsova E, Kollar M, Suchanek M, Koprivova H, Rysava R, Bednarova V, Tesar V, Hruskova Z. Biomarkers of fibrosis, kidney tissue injury and inflammation may predict severity and outcome of renal ANCA - associated vasculitis. Front Immunol. 2023 Mar 20;14:1122972. doi: 10.3389/fimmu.2023.1122972. PMID: 37020541; PMCID: PMC10067901. | Lire le résumé |
| Machet T, Quéméneur T, Ledoult E, Mesbah R, Lebas C, Hachulla, E, Pokeerbux MR, Rituximab resistance at 3 months of induction therapy in newly diagnosed or relapsing ANCA associated vasculitis: a French multicentre study, Joint Bone Spine (2023) | Lire le résumé |
| Culerrier J, Nguyen Y, Karadag O, Yasar Bilge S, Yildrim TD, Ögüt TS, et al. Characteristics and outcome of ANCA-associated vasculitides induced by anti-thyroid drugs: a multicenter retrospective case-control study. Rheumatol Oxf Engl. 24 juin 2023;kead319. | Lire le résumé |
| Partalidou S, Mamopoulos A, Dimopoulou D, Sarafidis P, Dimitroulas T. Pregnancy outcomes in ANCA-associated vasculitis patients: A systematic review and meta-analysis. Joint Bone Spine. 5 juill 2023;90(6):105609. | Lire le résumé |
| Bloom JL, Pickett-Nairn K, Silveira L, Fuhlbrigge RC, Cuthbertson D, Akuthota P, et al. The Association Between Age at Diagnosis and Disease Characteristics and Damage in Patients with ANCA-Associated Vasculitis. Arthritis Rheumatol Hoboken NJ. 11 juill 2023. | Lire le résumé |
| Rubenstein E, Maldini C, Vaglio A, Bello F, Bremer JP, Moosig F, et al. Cluster Analysis To Explore Clinical Subphenotypes Of Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss). J Rheumatol. 21 sept 2023;jrheum.2023-0325. | Lire le résumé |
| Khoudour N, Delestre F, Jabot‐Hanin F, Jouinot A, Nectoux J, Letouneur F, et al. Association Between Plasma Rituximab Concentration and the Risk of Major Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitides During Rituximab Maintenance Therapy. Arthritis Rheumatol. 13 août 2023;art.42556 | Lire le résumé |
| Florence Delestre, Pierre Charles, Alexandre Karras, Christian Pagnoux, Antoine Néel, Pascal Cohen, et al. Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials. Ann Rheum Dis. 2 nov 2023;ard-2023-224623 | Lire le résumé |
| Almaani S, Song H, Suthanthira M, Toy C, Fussner LA, Meara A, et al. Urine and Plasma Complement Ba Levels During Disease Flares in Patients With Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. Kidney Int Rep. nov 2023;8(11):2421‑7 | Lire le résumé |
| Lodka D, Zschummel M, Bunse M, Rousselle A, Sonnemann J, Kettritz R, et al. CD19-targeting CAR T cells protect from ANCA-induced acute kidney injury. Ann Rheum Dis. 5 janv 2024;ard-2023-224875 | Lire le résumé |
| Wechsler ME, Nair P, Terrier B, Walz B, Bourdin A, Jayne DRW, et al. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med. 7 mars 2024;390(10):911‑21 | Lire le résumé |
| Prskalo L, Skopnik CM, Goerlich N, Freund P, Wagner L, Grothgar E, et al. Urinary CD4+ T Cells Predict Renal Relapse in ANCA-Associated Vasculitis. J Am Soc Nephrol [Internet]. 17 janv 2024 [cité 5 mars 2024]; Disponible sur internet | Lire le résumé |
| Junek ML, Merkel PA, Vilayur E, Wald R, Khalidi N, Jayne D, et al. Risk of Relapse of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in a Randomized Controlled Trial of Plasma Exchange and Glucocorticoids. Arthritis Rheumatol. 14 mars 2024 | Lire le résumé |
| Fussner LA, Flores-Suárez LF, Cartin-Ceba R, Specks U, Cox PG, Jayne DRW, et al. Alveolar Hemorrhage in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Results of an International Randomized Controlled Trial (PEXIVAS). Am J Respir Crit Care Med. 1 mai 2024;209(9):1141‑51 | Lire le résumé |
| Thiel J, Schmidt FM, Lorenzetti R, Troilo A, Janowska I, Nießen L, et al. Defects in B-lymphopoiesis and B-cell maturation underlie prolonged B-cell depletion in ANCA-associated vasculitis. Ann Rheum Dis. 8 juin 2024;ard-2024-225587. | Lire le résumé |
| Gisslander K, White A, Aslett L, Hrušková Z, Lamprecht P, Musiał J, et al. Data-driven subclassification of ANCA-associated vasculitis: model-based clustering of a federated international cohort. Lancet Rheumatol. 22 août 2024;S2665-9913(24)00187-5 | Lire le résumé |